Technology & innovation

This archive covers technology and innovation breakthroughs that improve lives, protect the environment, and expand human possibility. From medical devices to clean energy tools, the stories here focus on what’s working and who’s making it happen.

Depiction of DNA, for article on gene therapy for inherited deafness

U.S. FDA approves first-ever gene therapy for inherited deafness, free to patients

By / / Good News For Humankind

Gene therapy can now restore hearing to children born deaf — and Regeneron is giving it away free to U.S. families.
In a trial of 20 children with rare OTOF mutations, 16 gained meaningful hearing within six months, and five regained normal hearing, including the ability to hear whispers. Instead of charging the millions per child that’s common for rare-disease therapies, Regeneron chose a different path. Beyond the families it directly helps, the decision hints at a quietly radical idea: that breakthrough medicine for rare conditions doesn’t have to come with a breathtaking price tag. Called Otarmeni, the one-time treatment uses two harmless viruses to deliver working copies of the OTOF gene deep into the inner ear, restoring otoferlin, the protein the cochlea needs to turn sound into signals the brain can read. Its maker, Regeneron, says it will offer the therapy free to patients in the U.S. Doctors who ran the trial described children responding to their parents’ voices, and to music, for the first time.
This particular genetic form of deafness is rare, affecting roughly 50 babies born in the U.S. each year. But researchers believe the breakthrough cracks open the door to gene therapies for many other inherited conditions worldwide.

Finger prick insulin injection, for article on once-weekly insulin

Once-weekly insulin wins U.S. approval, cutting 365 injections a year to 52

By / / Good News For Humankind

Once-weekly insulin just became reality in the U.S., dropping the routine for many adults with type 2 diabetes from 365 shots a year to about 52. The FDA approved Awiqli after four phase 3 trials, covering 2,680 adults, found it matched or outperformed daily basal insulin in lowering blood glucose. For people already taking a weekly GLP-1 medication, pairing the two could mean far fewer injection days and one less thing to remember. Doctors are urging thoughtful, individualized use, especially around hypoglycemia risk and affordability. Still, with more than 500 million adults living with diabetes worldwide, treatments that make daily life easier are a quietly powerful step forward for global health.

Child getting hearing test, for article on gene therapy for deafness

U.S. FDA approves first gene therapy for inherited deafness, offered free to U.S. patients

By / / Good News For Humankind

Gene therapy can now restore hearing to children born deaf — and Regeneron is giving it away free to U.S. families. In a trial of 20 children with rare OTOF mutations, 16 gained meaningful hearing within about five months, and several were brought to essentially normal hearing. One toddler covered his ears when an ambulance siren passed — his first sign of sound. Instead of charging up to $4 million per child, as is common for rare-disease therapies, Regeneron chose a different path entirely. Beyond the families it directly helps, the decision hints at a quietly radical idea: that breakthrough medicine for rare conditions doesn’t have to come with a breathtaking price tag.

Cancer patient reading a book, for article on pre-surgery immunotherapy

Bowel cancer patients see zero relapses three years after new immunotherapy

By / / Good News For Humankind

Bowel cancer patients in a small U.K. trial saw zero relapses nearly three years after receiving immunotherapy before surgery — a striking result for all 32 participants, even those who still had traces of cancer after treatment. By comparison, the standard path of surgery followed by chemotherapy sees roughly one in four patients relapse within three years. The trial focused on people with a specific genetic profile that makes tumors more visible to the immune system, sparing them months of post-surgery chemo. One participant described the cancer “melting away” before his operation. If larger trials confirm the approach, it could reshape how a meaningful slice of bowel cancer cases are treated worldwide.

Two sets of hand holding newborn baby, for article on Coartem Baby malaria treatment

W.H.O. approves world’s first malaria treatment for newborn babies

By / / Good News For Humankind

Newborn babies with malaria finally have a medicine made just for them. Coartem Baby, a cherry-flavored tablet that dissolves into breast milk or water, just earned World Health Organization prequalification — a green light that opens the door to public health systems across sub-Saharan Africa. For decades, doctors had to guess at doses using drugs built for older children, even as research showed infants were getting infected too. Ghana has already begun rolling it out, and Novartis has committed to what it calls “largely not-for-profit pricing” in malaria-endemic regions. Alongside new vaccines and better bed nets, it’s a quiet but meaningful sign that the fight against malaria — which still kills hundreds of thousands of children a year — is reaching the patients it had long overlooked.

Holding a nasal spray, for article on prehospital stroke nasal spray

Hong Kong researchers develop world-first nasal spray for stroke, cutting damage 80%

By / / Good News For Humankind

A nasal spray for stroke, developed at the University of Hong Kong, cut brain damage by more than 80% when given within 30 minutes of an ischemic stroke in preclinical studies. The idea is beautifully simple: tiny particles travel from the nose directly along nerve pathways to the brain, sidestepping the blood-brain barrier that derails most neurological drugs. Designed to be as easy to use as an EpiPen, it could let a bystander start protecting brain cells before the ambulance even arrives. Clinical trials are still years away, but if it holds up, this kind of “protection-first” thinking could reshape emergency care for stroke patients everywhere — especially the 85% who currently never reach treatment in time.

Flexbase redox flow battery in Switzerland, for article on redox flow battery

Switzerland begins work on the world’s most powerful redox flow battery

By / / Good News For Humankind

A redox flow battery rising from a 27-meter pit in northern Switzerland will become the world’s most powerful, capable of running 210,000 homes for a full day once it comes online in 2029. Unlike the lithium-ion batteries in our phones, this one stores energy in two liquid electrolytes pumped through a membrane — a design that’s non-flammable, almost fully recyclable, and built to cycle indefinitely without wearing out. It can respond to grid swings in milliseconds, soaking up excess wind power and releasing it when nearby AI data centers need a steady surge. Projects like this hint at what a renewables-first grid actually looks like: not just cleaner generation, but storage patient and powerful enough to make wind and solar genuinely dependable.

Scientist filling tubes, for article on reversible male contraception

Cornell researchers achieve first reversible male birth control in mice

By / / Good News For Humankind

Reversible male birth control just cleared a major hurdle: in a new Cornell study, male mice stopped producing sperm entirely after three weeks of treatment, then bounced back to full fertility within six weeks of stopping. The approach skips hormones altogether, targeting a specific window of sperm development in the testis so libido and other traits stay untouched. Even better, the mice went on to father healthy pups who were themselves fertile. The researchers are now testing new molecular targets and hope to launch a company within two years to move toward human trials. If the science holds up across species, it could finally give men a real long-acting option — and ease a contraceptive burden women have shouldered alone for generations.

Medical researcher in a lab examining vials related to asthma and COPD treatment and mRNA vaccine development, for article on benralizumab injection, for article on mRNA lung cancer vaccine

Doctors hail first breakthrough in asthma and COPD treatment in 50 years

By / / Good News For Humankind

Benralizumab, a single injection given during an asthma or COPD attack, outperformed the steroid pills that have been the only emergency option since the 1970s. In a King’s College London trial of 158 patients, those who got the shot had four times fewer treatment failures over 90 days, along with easier breathing and fewer follow-up visits. Because steroids carry real risks with repeated use — diabetes, osteoporosis, and more — a genuine alternative could change daily life for millions of people who live in fear of the next flare-up. After a half-century of stalled progress on diseases that claim 3.8 million lives a year, this feels like the door finally opening.

Researcher examining brain scan imagery for an article about Alzheimer's prevention trial results

U.S. researchers cut Alzheimer’s risk by half in first-ever prevention trial

By / / Good News For Humankind

Alzheimer’s prevention may have reached a turning point after a landmark trial showed that removing amyloid plaques before symptoms appear can cut the risk of developing the disease by roughly 50%. Researchers at Washington University School of Medicine studied people with rare genetic mutations that make Alzheimer’s nearly inevitable, finding that early, aggressive treatment can genuinely alter the disease’s course. The results, published in The Lancet Neurology, mark the first time any intervention has shown potential to prevent Alzheimer’s from appearing at all, not merely slow its progression. That distinction matters enormously, since amyloid begins accumulating in the brain two decades before symptoms emerge.